Citalopram

Basic citalopram information

• INN (international nonproprietary name): Citalopram.
• Brand names available in the United Kingdom: Cipramil; generic citalopram (e.g. Teva, Sandoz).
• ATC code: N06AB04.
• Forms and strengths: film-coated tablets 10 mg, 20 mg, 40 mg; oral drops 40 mg/mL.
• Manufacturers in the United Kingdom: Lundbeck (originator, Cipramil); generics from manufacturers such as Teva, Zentiva, Sandoz and Torrent.
• Registration status in the United Kingdom: not specified.
• OTC / Rx classification: Prescription only (Rx).

Legal status and availability in the UK

In our online pharmacy, citalopram is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Many patients want to know how quickly antidepressant effects begin.

Citalopram is commonly used in UK primary care for moderate-to-severe depression and produces symptom improvement within 1–4 weeks.

Greater benefit is often seen by 6–8 weeks, matching standard antidepressant timelines in UK practice.

Adherence is a key driver of outcome, and continuing treatment for at least 6 months after remission reduces relapse risk.

Initial prescriptions typically originate from GPs or secondary‑care psychiatrists, and community pharmacists play a practical role in adherence counselling and side‑effect management.

• Expected course: improvement often starts within 1–4 weeks; sleep and appetite may change early; sexual side effects may appear later.
• Common challenges: early nausea, sleep disturbance, perceived slowness of effect, and worry about withdrawal if stopped abruptly.

Standard adult starting dose is 20 mg/day with maximum 40 mg/day for most adults and a recommended elderly cap of 20 mg/day.

For further local guidance, see NHS and MHRA advice on antidepressant monitoring.

Indications and expanded uses

People often ask what citalopram is licensed to treat.

In the UK, citalopram is licensed for depressive illness and for panic disorder with or without agoraphobia.

Specialists sometimes also use citalopram off-label for social phobia and obsessive‑compulsive disorder where evidence supports benefit.

Off‑label uses such as chronic pain or menopausal mood complaints are occasionally seen but require specialist oversight because evidence is variable.

• MHRA‑approved indications: depressive illness; panic disorder.
• Off‑label uses (with specialist input): social phobia, OCD.
• Other off‑label uses: chronic pain, menopausal mood symptoms—use with caution and review.

Specialist review is recommended for long‑term or off‑label prescribing.

Composition and brand landscape

Patients often ask whether generics are the same as branded products.

Generic citalopram is widely available in the UK, with Lundbeck as the originator and major generics supplied by Teva, Sandoz and Zentiva.

Bioequivalence studies support that licensed generics match reference products for clinical effect.

Typical tablet strengths in the UK are 10 mg, 20 mg and 40 mg, and oral drops are also available.

• Switching guidance: pharmacists advise that any switch between brand and generic should be explained and documented by the GP or pharmacist.
• Storage: store below 25°C and keep in original packaging until use.

Some patients request a specific brand for perceived tolerability reasons.

Contraindications and special precautions

Patients rightly worry about dangerous interactions and heart checks.

MHRA safety communications list absolute contraindications including hypersensitivity to SSRIs, concurrent use with MAOIs or within two weeks of MAOI discontinuation, and use with pimozide or other recognised QT‑prolonging drugs.

Cardiovascular safety reviews point to increased QT risk at doses above 20 mg in the elderly or when combined with interacting medicines.

UK clinicians routinely screen GP medication lists and ask about over‑the‑counter and herbal products such as St John’s wort because of interaction risk.

• Absolute contraindications: hypersensitivity to citalopram or other SSRIs; concurrent MAOI use or within 2 weeks; use with pimozide or other QT‑prolonging drugs.
• Relative contraindications / caution: history of seizures, bipolar disorder, unstable cardiac disease, severe liver or renal dysfunction.

Definition: QT prolongation is an extended heart electrical interval on ECG that can increase arrhythmia risk.

Definition: MAOI interaction means combined use can cause serotonin syndrome and is therefore contraindicated.

Where indicated, an ECG is advised and suspected adverse reactions should be reported via the Yellow Card scheme.

Dosage guidelines

How should I take citalopram and what if I miss a dose?

National formularies and MHRA guidance specify a standard adult starting dose of 20 mg once daily, with a maximum daily dose of 40 mg for most adults.

Elderly patients and those with hepatic impairment are generally limited to a maximum of 20 mg/day due to QT and metabolism concerns.

Clinical practice often starts frail or anxious patients on 10 mg and titrates upwards as tolerated.

• Missed dose checklist: take as soon as remembered unless close to the next dose; do not double up.
• Overdose action: seek urgent medical attention; symptoms may include nausea, tremor, dizziness and arrhythmia.
• Tapering: reduce gradually under clinician supervision to minimise withdrawal symptoms.

Interactions overview

Which medicines must not be mixed with citalopram?

Key interactions include MAOIs (risk of serotonin syndrome), other QT‑prolonging medicines and drugs affecting CYP metabolism that change plasma levels.

Combined serotonergic agents, certain antipsychotics and pimozide are higher‑risk combinations which should be avoided or managed with specialist input.

Community pharmacists in the UK commonly check for OTC and herbal medicines and advise patients about alcohol and caffeine when dispensing citalopram.

Report suspected adverse reactions to the Yellow Card scheme as part of routine pharmacovigilance.

Comparable medicines and preferences

How does citalopram compare with other antidepressants commonly used in the UK?

Comparative reviews suggest escitalopram and sertraline are common alternatives with differing tolerability and interaction profiles.

NHS prescribing choices are typically guided by prior patient response, side‑effect considerations and comorbidities.

• Pros of citalopram: established record, widely available as a generic.
• When to refer: consider psychiatry if poor response, intolerable side effects or complex comorbidity.

Frequently asked questions

Q: When will I feel better?

A: Many people notice improvement within 1–4 weeks, with full effect by about 6–8 weeks.

Q: Will it affect my sex life?

A: Sexual dysfunction is a known side effect; discuss options with your GP or pharmacist if it arises.

Q: Do I need an ECG?

A: An ECG is recommended only if you are elderly, have cardiac disease or are taking interacting drugs, following MHRA guidance.

Q: How should I stop taking it?

A: Taper slowly under clinician supervision to reduce withdrawal symptoms; do not stop abruptly.

Remember the standard adult start dose is 20 mg/day and elderly maximum is 20 mg/day in many cases.

For adverse reactions, consider reporting via the Yellow Card scheme and consult NHS guidance for personalised advice.

Guidelines for proper use

What should pharmacists tell patients at dispensing?

Start citalopram at the recommended dose and explain that improvement may take several weeks.

Provide clear written instructions on dose, timing and missed‑dose advice and give a taper plan for eventual discontinuation.

Advise patients to avoid alcohol while establishing treatment and to report any unusual symptoms such as palpitations or severe dizziness.

• Pharmacist counselling checklist: explain dosing time, likely side effects, missed‑dose rules, how to taper, and when to seek urgent help.
• Stepwise patient plan: start, monitor weeks 1–4, review at 6–8 weeks, continue 6 months after remission, plan taper.

Legal classification: prescription-only medicine (Rx); store below 25°C and keep oral solution tightly sealed.

Signpost patients to NHS patient portals, MHRA Yellow Card reporting and their local pharmacy for follow‑up.

Delivery across the United Kingdom